OBJECT DRUGS
PRECIPITANT DRUGS
Antimicrobials:
- Ciprofloxacin (Cipro, etc.)
- Clarithromycin (Biaxin, etc.)
- Erythromycin (E-Mycin, etc.)
- Fluconazole (Diflucan)
- Itraconazole (Sporanox, etc.)
- Ketoconazole (Nizoral, etc.)
- Posaconazole (Noxafil)
- Quinupristin (Synercid)
- Telithromycin (Ketek)
- Troleandomycin (TAO)
- Voriconazole (Vfend)
Comment:
Bedaquiline is metabolized by CYP3A4 and concurrent administration of CYP3A4 inhibiting antimicrobials may increase the risk of bedaquiline toxicity. Bedaquiline can produce hepatotoxicity and can prolong the QTc interval, thus increasing the risk of ventricular arrhythmias.
Class 3: Assess Risk & Take Action if Necessary
- Consider Alternative:
- Azole Antifungals: Itraconazole and ketoconazole are potent inhibitors of CYP3A4; fluconazole appears weaker, but in larger doses it also inhibits CYP3A4. Terbinafine (Lamisil) does not appear to affect CYP3A4, and would not be expected to interact with bedaquiline.
- Macrolide Antibiotics: Unlike erythromycin, clarithromycin and troleandomycin, azithromycin (Zithromax) and dirithromycin* do not appear to inhibit CYP3A4. (*not available in US)
- Telithromycin: The use of azithromycin (Zithromax) or a quinolone antibiotic other than ciprofloxacin should be considered.
- Monitor: If the combination is used, monitor for evidence of hepatotoxicity and monitor the ECG for evidence of QTc prolongation.